Drugs / Arubicin
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07642453 Background | Jun 2026 → Jun 2028 expected | acute myeloid leukemia | Hematology department of the 920th hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Arubicin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07642453 ↗ |
| Route | Intravenous | “12-14 mg/m² on days 1, 3, 5, and 7 (IV infusion)” NCT07642453 ↗ |